India’s vaccine power at UNGA: PM Modi mentions mRNA vaccine for Covid-19

Prime Minister Narendra Modi was referred to the mRNA vaccine being developed by Gennova Biopharma during his address at the United Nation General Assembly (UNGA)

By BioVoice News Desk -

September 26, 2021

New Delhi: During his address at the United Nation General Assembly (UNGA), Prime Minister Narendra Modi on September 25, 2021, stated that India’s first mRNA vaccine is in final stages. He was referring to the mRNA vaccine being developed by Gennova Biopharma, a subsidiary of Pune based Emcure Pharmaceuticals.

While addressing the UNGA’s 76^th session, PM Modi said, “India has developed the world’s first DNA vaccine. An m-RNA vaccine is in the final stages of development. Indian scientists are also developing a nasal vaccine against COVID19.”

The Drug Controller General of India, had approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals Limited (“Gennova”) back in August.

Gennova had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India’s National Regulatory Authority (NRA).

The Vaccine Subject Expert Committee (SEC) had reviewed the interim Phase I data, and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.

The study is being conducted in India at approximately 10-15 sites in Phase II and 22-27 sites in Phase III. Gennova is using the DBT-ICMR clinical trial network sites for this study.

While addressing the UNGA’s 76th session, PM Modi said, “India has developed the world’s first DNA vaccine. An m-RNA vaccine is in the final stages of development. Indian scientists are also developing a nasal vaccine against COVID19.”

The Drug Controller General of India, had approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals Limited (“Gennova”) back in August.

Gennova had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India’s National Regulatory Authority (NRA).

The Vaccine Subject Expert Committee (SEC) had reviewed the interim Phase I data, and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.

The study is being conducted in India at approximately 10-15 sites in Phase II and 22-27 sites in Phase III. Gennova is using the DBT-ICMR clinical trial network sites for this study.

Face to Face

Chat with BioVoice

R&D

Events

While addressing the UNGA’s 76^th session, PM Modi said, “India has developed the world’s first DNA vaccine. An m-RNA vaccine is in the final stages of development. Indian scientists are also developing a nasal vaccine against COVID19.”